• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes: a dose-response meta-analysis of large prospective studies
Conclusions Inverse non-linear dose–response associations suggest substantial protection against a range of chronic disease outcomes from small increases in non-occupational physical activity in inactive adults. PROSPERO registration number CRD42018095481.
Source: British Journal of Sports Medicine - July 20, 2023 Category: Sports Medicine Authors: Garcia, L., Pearce, M., Abbas, A., Mok, A., Strain, T., Ali, S., Crippa, A., Dempsey, P. C., Golubic, R., Kelly, P., Laird, Y., McNamara, E., Moore, S., de Sa, T. H., Smith, A. D., Wijndaele, K., Woodcock, J., Brage, S. Tags: Open access, BJSM Reviews with MCQs, BJSM Systematic review Source Type: research

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - August 21, 2019 Category: General Medicine Source Type: research

The international St-aging system as a prognostic marker in general senior population: Findings from the EPIDOS cohort study.
In conclusion, community-dwelling older women with abnormal ISS had shorter survival time than the others, suggesting that ISS could be considered as a universal prognostic "aging system" rather than a specific MM "staging system". PMID: 31387843 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - August 2, 2019 Category: Internal Medicine Authors: Pouzoullic M, Schott AM, Sánchez-Rodríguez D, Bataille R, Annweiler C, SOCOS group Tags: Eur J Intern Med Source Type: research

September Is Childhood Obesity Month -- Get The Facts
The obesity epidemic continues to dominate headlines--and for good reason. Obesity is a leading cause of heart disease, diabetes, high blood pressure, and stroke. Many of these conditions occur in adults but often begin in childhood. This September is National Childhood Obesity Awareness Month. By knowing the facts and taking steps to help your children live a healthier lifestyle, childhood obesity and its resulting complications may be prevented. The Facts According to the Centers for Disease Control & Prevention (CDC), one in three children in the U.S. is overweight or obese. Childhood obesity doubled in children and ...
Source: Healthy Living - The Huffington Post - September 28, 2016 Category: Consumer Health News Source Type: news

Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study Epidemiology
Conclusion The magnitude of subsequent CVD risk varies according to cancer subtype and by the presence of CVRFs. Overall survival in survivors who develop CVD is poor, emphasizing the need for targeted prevention strategies for individuals at highest risk of developing CVD.
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Armenian, Xu, Ky, Sun, Farol, Pal, Douglas, Bhatia, Chao Tags: Population and observational studies (SEER, WHI observational, etc.) Epidemiology Source Type: research

2016 Moon Shot for Cancer: Focus on Prevention
It is now 2016, and Americans hope for a brighter, healthier new year. Are Americans healthier today than they were last year or the year before? Will there be fewer people diagnosed with cancer? According to the American Cancer Society, it is projected that in 2016 there will be 1,685,210 new cancer cases and 595,690 deaths due to cancer. This is an increase over previous years. While it is true that the death rate for several cancers has decreased (due mostly to better screening and earlier diagnosis), it is also true that several cancers are on the rise, including cancers of the thyroid, liver, pancreas, kidney, small i...
Source: Healthy Living - The Huffington Post - February 1, 2016 Category: Consumer Health News Source Type: news

Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study.
CONCLUSION: The magnitude of subsequent CVD risk varies according to cancer subtype and by the presence of CVRFs. Overall survival in survivors who develop CVD is poor, emphasizing the need for targeted prevention strategies for individuals at highest risk of developing CVD. PMID: 26834065 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - February 1, 2016 Category: Cancer & Oncology Authors: Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C Tags: J Clin Oncol Source Type: research

Influence of Conventional Cardiovascular Risk Factors and Lifestyle Characteristics on Cardiovascular Disease After Hematopoietic Cell Transplantation Health Services and Outcomes
Conclusion Attention of clinicians to conventional cardiovascular risk factors and modifiable lifestyle characteristics offers hope of reducing serious cardiovascular morbidity after HCT.
Source: Journal of Clinical Oncology - January 17, 2014 Category: Cancer & Oncology Authors: Chow, Baker, Lee, Flowers, Cushing-Haugen, Inamoto, Khera, Leisenring, Syrjala, Martin Tags: Leukemia, Lymphoma, Myeloma, Outcomes Research Health Services and Outcomes Source Type: research